First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.

被引：0
|
作者：
Plummer, R
Middleton, M
Wilson, R
Jones, C
Evans, J
Robson, L
Steinfeldt, H
Kaufman, R
Reich, S
Calvert, AH
机构：
[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[2] Churchill Hosp, Oncol Unit, Oxford OX3 7LJ, England
[3] Queens Univ Belfast, Dept Oncol, Belfast, Antrim, North Ireland
[4] Beatson Oncol Ctr, Dept Med Oncol, Glasgow, Lanark, Scotland
[5] Canc Res UK, London, England
[6] Pfizer Global Res & Dev, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：208S / 208S
页数：1
相关论文
共 50 条
  • [1] Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
    Plummer, Ruth
    Jones, Christopher
    Middleton, Mark
    Wilson, Richard
    Evans, Jeffrey
    Olsen, Anna
    Curtin, Nicola
    Boddy, Alan
    McHugh, Peter
    Newell, David
    Harris, Adrian
    Johnson, Patrick
    Steinfeldt, Heidi
    Dewji, Raz
    Wang, Diane
    Robson, Lesley
    Calvert, Hilary
    CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7917 - 7923
  • [2] A phase I study of bortezomib (BTZ) and temozolomide (TMZ) in patients with advanced solid tumors
    Portnow, J.
    Koehler, S.
    Cristea, M. C.
    Chow, W. A.
    Chung, V. M.
    Lim, D.
    Morgan, R.
    Shibata, S.
    Frankel, P. H.
    Synold, T. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.
    El-Khoueiry, Anthony B.
    Ning, Yan
    Yang, Dongyun
    Cole, Sarah
    Kahn, Michael
    Zoghbi, Marwan
    Berg, Jennifer
    Fujimori, Masamoto
    Inada, Tetsuhi
    Kouji, Hiroyuki
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
    Razak, Albiruni R. A.
    Soerensen, Morten Mau
    Mahipal, Amit
    Shacham, Sharon
    Yau, Cindy Y. F.
    Lassen, Ulrik Niels
    McCauley, Dilara
    Cooksey, Jennifer
    Tan, David Shao Peng
    Saint-Martin, Jean-Richard
    Landesman, Yossi
    Pond, Gregory
    Oza, Amit M.
    Kauffman, Michael
    Siu, Lillian L.
    Mirza, Mansoor Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in patients with advanced solid tumors.
    Eads, Jennifer Rachel
    Krishnamurthi, Smitha S.
    Saltzman, Joel N.
    Meropol, Neal J.
    Bokar, Joseph A.
    Gibbons, Joseph
    Koon, Henry B.
    Sharma, Neelesh
    Savvides, Panayiotis
    Pink, John
    Xu, Yan
    Beumer, Jan Hendrik
    Fu, Pingfu
    Beatty, Kristi
    Kane, Donna
    Rodal, Mary Beth
    Czalkiewicz, Julianne
    Riendeau, John
    Gerson, Stanton L.
    Dowlati, Afshin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
    De Bono, Johann Sebastian
    Mina, Lida A.
    Gonzalez, Michael
    Curtin, Nicola J.
    Wang, Evelyn
    Henshaw, Joshua W.
    Chadha, Manpreet
    Sachdev, Jasgit C.
    Matei, Daniela
    Jameson, Gayle S.
    Ong, Michael
    Basu, Bristi
    Wainberg, Zev A.
    Byers, Lauren Averett
    Chugh, Rashmi
    Dorr, Andrew
    Kaye, Stanley B.
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
    Mateo, Joaquin
    De Bono, Johann Sebastian
    Ramanathan, Ramesh K.
    Lustberg, Maryam B.
    Zivi, Andrea
    Basset, Dawn
    Ng, Matthew
    Young, Anna-Mary
    Garrett, Michelle
    Decordova, Shaun
    Raynaud, Florence I.
    Yap, Timothy Anthony
    Zukiwski, Alexander A.
    Proniuk, Stefan
    Shapiro, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.
    Wagner, Andrew J.
    Banerji, Udai
    Mahipal, Amit
    Somaiah, Neeta
    Hirsch, Heather Anne
    Fancourt, Craig
    Levonas, Amy
    Lam, Raymond
    Meister, Amy
    Kemp, Ramon Karmel
    Knox, Clayton
    Rose, Shelonitda
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Phase I trial of irinotecan and epirubicin in patients with advanced solid tumors.
    Gold, PJ
    Refice, S
    West, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 164S - 164S
  • [10] Preliminary results of pamiparib (BGB-290), a PARP1/2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumors
    Johnson, M.
    Galsky, M.
    Barve, M.
    Goel, S.
    Park, H.
    Du, B.
    Mu, S.
    Ramakrishnan, V.
    Wood, K.
    Wang, V.
    Lakhani, N.
    ANNALS OF ONCOLOGY, 2018, 29 : 138 - 138
12345